Actively Recruiting
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
Led by University Hospital, Bordeaux · Updated on 2025-07-14
90
Participants Needed
10
Research Sites
466 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Bordeaux
Lead Sponsor
M
Ministry for Health and Solidarity, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47% declare a complete disease after five years. The aim of this study is to assess in this particular population the preventive effect of an anti-platelet treatment.
CONDITIONS
Official Title
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years old and under 85 years old
- Positive anti-nuclear antibodies (AAN ≥ 1/160) specific to systemic sclerosis such as anti-Scl70, anti-centromere, or anti-RNA polymerase III
- Presence of Raynaud phenomenon confirmed by a physician
- Affiliated with a health insurance system
- Willingness to participate and signed informed consent
You will not qualify if you...
- Diagnosis of systemic sclerosis according to ACR/EULAR 2013 criteria
- Presence of skin fibrosis at screening
- Current antiplatelet treatment
- Contraindications to clopidogrel
- Use of immunosuppressive agents at screening
- Use of anticoagulant treatment at screening
- Pregnant or breastfeeding women
- Women of childbearing age not using effective contraception during the 24-month treatment
- Adults under legal protection (incompetent adults)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
CH de la Cote Basque - service de rhumatologie
Bayonne, France
Actively Recruiting
2
CHU de Bordeaux - service de Médecine Interne et Maladies Infectieuses
Bordeaux, France
Not Yet Recruiting
3
CHU de Bordeaux - service de rhumatologie
Bordeaux, France
Actively Recruiting
4
CHU de Brest - service de rhumatologie
Brest, France
Actively Recruiting
5
CHU de Grenoble Alpes - service de médecine vasculaire
Grenoble, France
Not Yet Recruiting
6
CH de Libourne - service de rhumatologie
Libourne, France
Actively Recruiting
7
CH de Mont-de-Marsan - service de rhumatologie
Mont-de-Marsan, France
Actively Recruiting
8
AP-HP - Hôpital Cochin - service de médecine interne
Paris, France
Actively Recruiting
9
CH de Pau - service de médecine interne
Pau, France
Actively Recruiting
10
CHU de Toulouse - service de médecine interne
Toulouse, France
Not Yet Recruiting
Research Team
M
Marie-Elise TRUCHETET, Prof
CONTACT
T
Thomas BARNETCHE, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here